Safety of NTX-253 in healthy adults and adults with stable schizophrenia
About this title
Read the official source — NCT07344948Understand this study
Who could participate?
Listed age limits: 18 years to 55 years.
What will I do during this study?
Adults aged 18 to 55 may be eligible as healthy volunteers or as people with stable schizophrenia. Depending on the study group, participants receive oral NTX-253 or placebo (an inactive comparison treatment) as a single dose or once daily for ten days. Researchers monitor safety, tolerability and how the study drug is processed by the body. This early-phase study is not designed to establish whether NTX-253 treats schizophrenia.
- Listed locations
- Los AlamitosSee all locations and recruitment
- Study phase
- Early phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 73
- Sponsor
- Neurosterix
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Early Phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT07344948
- Official title
Show the full official title
A First in Human, Phase 1/1b Study of Single and Multiple Ascending Dosing Administration of NTX110253 in Healthy Participants and Participants With Stable Schizophrenia
Recruitment & locations
Los Alamitos
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Neurosterix.
Does this study involve medication?
Yes. The study involves medication, including NTX-253 and Placebo.
Who can participate?
Listed age limits: 18 years to 55 years.
Is this study still recruiting?
The registry lists this study as recruiting.
